STUDresearch · Peptide
IGF-1 DES
Also known as
Des(1-3)IGF-1 · DES(1-3) IGF-1 · des(1-3)IGF-I · IGF1 DES · IGF-DES · IGF DES 1,3 · IGF-1 DES 1-3 · des-IGF-1 · Des-IGF-1 · truncated IGF-1 · rHuDES(1-3)IGF-1
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Some talk
Mixed
IM / SubQ
Growth factors
Mixed — usually discussed as a muscle-site injection, but systemic spillover and human DES pharmacokinetics remain unresolved.
What people say
IGF-1 DES is des(1–3)IGF-I, a truncated IGF-I analogue with reduced binding-protein affinity. Bodybuilding communities frame it as a short site-use growth factor, but no controlled human trial validates gray-market muscle use.
Doses people talk about
Amounts describe unverified products and mostly IM bodybuilding use. They are not recommendations, and co-use changes both interpretation and risk.
How it may feel
Reports range from strong localized pump, reduced repetitions and later soreness to no pump or glucose sensation at all. Combination reports describe several hours of hypoglycemic feeling, so neither a typical response nor product identity is established.
Single-muscle report25 mcg IM
One week into use, the author reported a strong pump but sharply reduced repetitions and unusual soreness; injection trauma was an alternative explanation.
Repeated site-use range40–80 mcg
Forum users debated pre-, intra- and post-workout timing; one detailed account described about 50 mcg per injection and an hour of pump.
Higher combination report150–200 mcg
One author reported feeling hypoglycemic for a couple of hours when PEG-MGF followed; the same author described less trouble around 80 mcg total.
Half-life & effect duration
- Half-life in the body
- Common community estimateAbout 20–30 minutes
- Other community estimateAbout 2–5 minutes
- Felt duration people report
- Pump accountAbout 1 hour
- Low-blood-sugar feeling · with PEG-MGFA couple of hours in one account
- Other accountNeither pump nor that sensation
Cycles people discuss
Legacy charts describe training-day blocks lasting roughly three to eight weeks with time off. These calendars are bodybuilding lore rather than human DES dose-finding or safety evidence.
Timing
Pre-workout and immediately post-workout camps coexist in community discussion. Their local-growth and food/glucose rationales are not validated timing or safety advantages; rest-day habits also differ by the reported goal.
Stacks
DES is commonly discussed with LR3, MGF or PEG-MGF, HGH and secretagogues. Glucose, growth and attribution risks compound, and the clearest adverse report reviewed involved PEG-MGF co-use.
Watch for
Glucose effects / uncertainty: DES users report everything from no hypoglycemia at high claimed amounts to feeling hypoglycemic for a couple of hours when 150–200 mcg DES was combined with PEG-MGF. Shaking, sweating, confusion or loss of consciousness are emergency symptoms, but these uncontrolled reports cannot establish a DES-specific rate or dose threshold.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No human parent-DES half-life was established in the checked evidence.
Forums repeat 20–30 minutes and sometimes 2–5 minutes. The primary comparison studied clearance of IGF-I, DES and LR3 in rats and showed binding-protein-dependent behavior without validating those human figures.
Species and route mismatch; no human concentration-time curve; gray-market identity, purity and assay behavior unknown.
- Gillespie et al. — Plasma clearance of IGF-I, des-(1-3)IGF-I and LR3IGF-I (opens in a new tab)Abstract: rat chronic-renal-failure model comparing IGF-I, des-(1–3)IGF-I and LR3IGF-I clearance, degradation, tissue distribution and binding; poorly binding analogues behaved differently as binding changed.Rat disease model; abstract does not provide a human DES half-life or validate gray-market IM use.
- r/Peptides — IGF DES experiences (opens in a new tab)Visible replies include claimed IM use up to 250 mcg with no pump or hypoglycemia and explicit doubt about product identity; another user reported broader size/definition and injury benefit without a documented amount.Unverified products, deleted authorship on one report, no glucose readings or controlled training comparison, and sourcing details are not reproduced.
Felt duration people report
Some users describe about an hour of pump or a couple of hours of hypoglycemic feeling; others report neither.
The hypoglycemic report involved PEG-MGF co-use. A separate user claimed no pump or hypoglycemia at amounts up to 250 mcg and doubted product identity.
Tiny uncontrolled sample, self-measured amounts, exercise and co-compound confounding, no glucose confirmation, and uncertain identity.
- r/Peptides — IGF1 DES timing and experience thread (opens in a new tab)Visible same-author discussion describes pre-workout and repeat intra-workout use, about 50 mcg per injection, an hour of pump/vascularity and perceived regional development; other users dispute timing and locality.No product verification, measurements or control for training, GH or other compounds; includes contradictory and promotional replies.
- r/Peptides — DES and PEG-MGF same-day discussion (opens in a new tab)Original and same-author follow-ups: claimed good results with each separately; combination use produced more hypoglycemic feeling, lasting a couple of hours at 150–200 mcg DES, with less trouble around 80 mcg total.Co-use prevents DES attribution; no glucose measurement, verified identity or clinical safety data.
- r/Peptides — IGF DES experiences (opens in a new tab)Visible replies include claimed IM use up to 250 mcg with no pump or hypoglycemia and explicit doubt about product identity; another user reported broader size/definition and injury benefit without a documented amount.Unverified products, deleted authorship on one report, no glucose readings or controlled training comparison, and sourcing details are not reproduced.
Other context in this card
- r/Peptides — IGF-1 DES working against me (opens in a new tab)Original and same-author replies: 25 mcg into a target muscle, one week of use, large pump but fewer repetitions and more soreness; another commenter raises injection trauma as an alternative.Single uncontrolled report, no glucose data, unverified product and immediate exercise after IM injection.
What people say
- Local hypertrophy talk: Fuller/more responsive trained muscles after multi-week site shots into lagging parts — heavily confounded by training volume, carbs, and stacks. forum
- Site-enhancement lore: IM into calves, rear delts, arms, pecs, etc. for regional size/shape; anecdote-heavy and not proven as permanent fiber-count gains in humans. forum
- Hyperplasia narrative: Community frames DES as better than LR3 for “new cell / satellite-cell” local growth because of the short intense free-peptide burst; this is pathway storytelling more than measured human fiber-count proof. forum
- Pump / fullness on dose days: Acute fullness and vascularity in the injected muscle with peri-dose carbs; hard to separate from glycogen, pump work, and water. anecdote
- Recovery feel: Some report easier next-session readiness or less localized DOMS in the target site. forum
- Nutrient uptake talk: Glucose and amino-acid transport into the dosed muscle is a common mechanism claim for post-workout pairing with carbs/protein. forum
- Connective-tissue / injury lore: Soft-tissue repair, collagen, and tendon talk — often when stacked with BPC-157 / TB-500 rather than as a standalone DES effect. forum
- Vs LR3 typology: DES = short/local site tool; LR3 = longer/systemic coverage — complementary roles in advanced charts, not a head-to-head superiority trial. forum
- Minimal long systemic exposure claim: Short half-life is sold as lower organ-growth risk than multi-week high systemic IGF — still theoretical; acute hypo and local overgrowth remain discussed. forum
- Stack confound: Very often stacked with HGH, insulin, AAS, LR3, MGF/PEG-MGF, or secretagogues — single-agent credit is unreliable. forum
- Potency claim range: Roughly ~2–10× activity vs native IGF-1 in simplified posts; ~5–10× and “~10× locally” are the most repeated numbers from in-vitro/animal potency lore. Some vendor copy claims DES “~5× LR3” for local hyperplasia — that ranking is community marketing, not a standard clinical ranking. lab
- Preclinical backdrop: des(1-3)IGF-1 studied for anabolic and gut/tissue effects in animals because low IGFBP binding raises free activity; leap to gray-market IM bodybuilding protocols remains unvalidated in humans. animal
Doses people talk about
- Per-site band (common threads): ~20–100 mcg per injection site. forum
- Per-session total (bilateral / multi-site): ~50–150 mcg total when split into left/right (or multiple heads) of the trained muscle is a widely repeated bodybuilding band. forum
- Beginner start (site work): ~20–50 mcg per injection, or ~40–60 mcg per side (~80–120 mcg session) to gauge tolerance and glucose. forum
- Intermediate band: ~50–80 mcg per muscle group / side once tolerance is known — charts vary (some use 50–75 mcg “per injection”). forum
- Advanced / upper community talk: ~75–100 mcg per injection, or up to ~100–120 mcg per muscle group bilaterally in aggressive logs; diminishing returns and sides often argued above ~100 mcg/day total. forum
- Conservative “research chart” band: Some protocol pages cite ~20–50 mcg once daily SC near trained muscle for 4–6 weeks — lower than classic bodybuilding site-split totals and not a trial dose. forum
- Daily ceiling lore: Vendor/forum copy often caps ~100 mcg/day total, split across 2–4 muscles pre- or post-workout — not a safety proof. forum
- Frequency: Training days only is the default for hypertrophy experiments (often ~3–5×/week matching the target muscle schedule). forum
- 1–2×/day talk: Some advanced or injury charts mention 1–2 injections/day; most hypertrophy lore is 1× around the trained session. forum
- Timing debate — post-workout camp: Inject immediately post-workout (often within ~10–15 min) into the trained muscle when blood flow and receptor talk peak; carbs planned in the same window. Strongly favored by some coaches who say pre-workout wastes the short half-life and raises hypo risk mid-session. forum
- Timing debate — pre-workout camp: Inject ~15–30 min pre into the target muscle so the free peptide is active during training (lactic-acid / “deformed receptor” forum lore is common but not clinical). forum
- Rest-day dosing: Many skip rest days for pure site-growth goals; injury charts may still dose near the site daily for short blocks. forum
- Carb pairing talk: Protocol summaries often pair dose with ~30–50 g fast carbs and a protein-forward meal; never intentionally deep-fasted. forum
- Bilateral split rule of thumb: Split the session total left/right (e.g., 50 mcg total → 25 mcg each side) so both heads of a lagging pair get coverage. forum
- Large-muscle multi-head talk: Quads, lats, pecs sometimes get multiple injection points within the same muscle for “coverage” — volume still kept small per stick. forum
- Missed dose: Skip and resume next training day — do not double-dose (additive hypo risk). forum
- Source uncertainty: Gray-market labels ≠ verified identity, purity, or stated mcg; underdosing/mislabel confounds every log. forum
- Framing: Community-discussed and research-chem protocol ranges only — not medical advice, not clinical prescriptions, not validated athletic protocols. No human trial has established a DES site-enhancement dose. forum
How it may feel
- 0–60 minutes post-injection: Reports conflict. One user described a strong pump but sharply fewer reps after 25 mcg into a trained muscle; another reported no extra pump or hypoglycemia despite claimed use up to 250 mcg. Product identity and injection-related soreness were unresolved. forumanecdote
- Same session (pre- or post-workout timing camps): Some report fuller pump/vascularity in the dosed muscle with food; others notice nothing cosmetic beyond injection logistics. anecdote
- Days 1–3: Little visual change; logs emphasize learning hypo response, bilateral split technique, and never dosing deep-fasted. forum
- Days 3–7: Pump/fuller feel in trained/dosed muscles appears in some logs when carbs and volume are high. forum
- Weeks 1–2: Checkpoint — does regional fullness/recovery justify multi-site IM shots and carb vigilance? Non-responders recheck surplus, progressive overload, sleep, and vial math. forum
- Weeks 2–4: Subjective regional size/shape claims most often land here if they land; not a steroid-like overnight flip. forum
- Weeks 4–6: Common stop-or-extend decision point for intensive lagging-part blocks; guides often cap continuous runs here. forum
- Weeks 4–8 (longer community runs): Some advanced protocols stretch to ~8 weeks then force time off for receptor-sensitivity lore; risk talk rises with length. forum
Cycles people discuss
- Core rule in lore: Short intensive blocks timed to a lagging-part or hard mesocycle — not a year-round daily peptide. forum
- Common hypertrophy length: ~3–4 weeks of training-day dosing for local experiments. forum
- Standard chart range: ~4–6 weeks on is the modal guide length across multiple protocol pages. forum
- Extended community runs: ~4–8 weeks appears in some advanced write-ups before a forced off period. forum
- Time off: Often ≥ on-period, or at least ~2–4 weeks off (many say ≥4 weeks) before re-running the same sites — receptor downregulation lore. forum
- Equal on/off template: 4 weeks on / 4 weeks off is a frequently repeated simple template. forum
- Injury micro-cycles: ~2–4 weeks near an injured site when stacked with BPC-157 / TB-500 is discussed as a shorter repair window. forum
- Pulse pattern: Dose only on days the target muscle is trained for specialization blocks. forum
- Why not continuous: Forums cite IGF1R desensitization, cumulative mitogenic concern, and local tissue-overgrowth risk with unbroken multi-month use. forum
- Re-runs: Later bulks for the same lagging region are common; long-term safety data for repeated gray-market DES cycles do not exist. forum
- Vs LR3 cycle culture: DES is often allowed slightly more frequent/training-tied use in lore because of short duration, but still capped in weeks not months; LR3 blocks are typically systemic daily for a short defined window. forum
- Exit triggers discussed: Recurrent hypo despite food, progressive disproportionate local growth or stiffness, severe headache/visual change, or any concerning new growth/lesion — community stop flags, not a complete medical algorithm. forum
Timing
- Half-life claims (community + protocol guides): ~20–30 minutes for DES and ~20–30 hours for LR3 are repeated forum figures. The checked primary clearance work was in rats and did not establish either as a human analog half-life. forumanimal
- Even shorter degradation talk: Older forum/product copy also cites ~2–5 minutes in humans. No supporting human DES concentration-time study was identified, so this remains unverified lore and cannot validate site timing or product identity. forum
- Why workout-tied: Minutes-scale duration → pre- or post-workout site shots, not once-daily depot systemic coverage. forum
- Glucose: Insulin-like hypo risk is still discussed despite short half-life; carbs around dosing are stressed, especially at higher mcg or with insulin/GH stacks. forum
- Class map: DES short/local; LR3 longer systemic; native free IGF short + high BP binding; MGF short local splice-variant talk; PEG-MGF extended local/systemic hybrid talk. forum
- Pre vs post (timing logic): Pre camp wants activity during mechanical tension; post camp wants receptors/blood flow after damage plus safer glucose management with food — both camps agree rest-day cold-muscle shots are lower priority for pure site growth. forum
- MGF co-timing lore: Classic forum charts sometimes put MGF immediately post-workout and DES or LR3 on a different schedule so growth-factor waves do not fully collide; exact spacing is community lore and varies. forum
- Why short: Poor IGFBP sequestration means free peptide is receptor-available but also cleared/degraded quickly — the same property sold as local potency. lab
- Local burst framing: Lower IGFBP binding + IM placement = brief unbound hit at the injection site (and whatever systemic free fraction escapes). forum
- Detection / sport: Growth-factor class substances are WADA-prohibited; tested athletes treat DES as high risk regardless of short half-life marketing. trial
More on what it is
- Why people use it: Framed as the short, high-potency “site/local” IGF for lagging-muscle shots around training, vs longer-acting systemic LR3. forum
- Mechanism talk: Free peptide hits IGF1R → PI3K/Akt/mTOR (protein synthesis, glucose/AA uptake) and MAPK pathways; satellite-cell activation and hyperplasia talk is the bro differentiator vs pure myofibrillar swelling. Insulin-like glucose disposal is the same pathway that drives hypo risk. forum
- What it is: Truncated analog of human IGF-1 missing the N-terminal tripeptide Gly-Pro-Glu (hence Des(1-3)); ~67 residues vs native 70. Research/vendor IDs often list CAS ~112603-35-7 and MW ~7.3–7.4 kDa. Gray-market research peptide — not an approved physique drug. trial
- Why more free locally: Losing the N-terminus (especially Glu3) sharply cuts IGF-binding-protein affinity — community/protocol write-ups often cite ~90% less IGFBP-3 binding and ~5–10× higher local potency vs native IGF-1 in simplified in-vitro comparisons. lab
- Evidence posture: Stronger cell/animal IGF biology (native and des forms studied in growth, gut, and muscle contexts) than large human physique RCTs. No controlled human trials validate gray-market DES for site-enhancement or adult hypertrophy. animal
- What it is not: Not HGH, not insulin, not IGF-1 LR3, not MGF/PEG-MGF, not mecasermin (native 70-aa rhIGF-1 / Increlex), not an FDA-approved muscle or injury drug. trial
- Regulatory / sport: Research-chem / gray-market peptide space; WADA S2 peptide hormones/growth factors — prohibited in and out of competition for tested athletes. trial
Stacks
- DES + LR3: Local short DES site pulses plus longer systemic LR3 coverage in the same block — glucose risk and complexity stack; advanced charts only. forum
- DES + MGF / PEG-MGF: Local growth-factor stack around hard training days; classic lore separates “early MGF / satellite proliferation” from later differentiation/protein-synthesis waves — schedules vary and evidence is community-level. forum
- DES + HGH: GH elevates systemic IGF-1 upstream while DES is the immediate local punch — expensive advanced protocol with more metabolic load. forum
- DES + MK-677: Oral GH-secretagogue baseline + local DES — appetite/water from MK plus DES hypo vigilance. forum
- DES + BPC-157 ± TB-500: Injury / soft-tissue recovery stack — DES for local anabolic/satellite talk, BPC/TB for repair-inflammation lore; sample injury charts sometimes use lower DES (~20–40 mcg near site) with BPC ~250–500 mcg and TB weekly loads that vary widely. forum
- DES + testosterone / AAS bulks: Systemic androgen foundation + DES for weak points — multi-drug confounds and side risk dominate advanced forums. forum
- DES + insulin (extreme caution): Nutrient-partitioning lore; both lower glucose — widely flagged as advanced-only or avoid outside supervised settings. forum
- Training + surplus: Progressive overload on the target muscle and peri-workout carbs are repeatedly credited when logs look good — non-pharmacologic half of the stack. forum
- DES + CJC-1295 (often no DAC) + Ipamorelin: Popular peptide framing — secretagogues for endogenous GH pulses, DES as training-day local hit; sample charts often show DES ~40–100 mcg PWO with Ipa ~100 mcg and CJC no DAC ~100 mcg class doses (vendor charts vary). forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Glucose effects / uncertainty: DES users report everything from no hypoglycemia at high claimed amounts to feeling hypoglycemic for a couple of hours when 150–200 mcg DES was combined with PEG-MGF. Shaking, sweating, confusion or loss of consciousness are emergency symptoms, but these uncontrolled reports cannot establish a DES-specific rate or dose threshold. forumanecdote
- Carb mitigation lore: Plan ~30–50 g fast carbs with the dose window; keep glucose tablets/juice available — do not rely on “feel bad then eat” alone. forum
- Injection site: Pain, redness, swelling, bruising, irritation from IM; worse with poor technique, large volume, or same-spot repetition. forum
- Local tissue overgrowth / disproportionate growth: Abuse lore for too-high or too-frequent site shots producing unnatural regional growth or stiffness if collagen remodeling is overdriven. forum
- Water retention / puffiness: Mild facial or limb fullness in some logs, especially when stacked with GH secretagogues or high carbs. anecdote
- Headache, nausea, fatigue, joint ache: Minority multi-compound logs; causality muddy under polypharmacy. forum
- Organ growth / visceral concern: Less emphasized than with long systemic LR3 or high HGH, but high-dose or chronic IGF-axis excess lore still includes unwanted tissue/organ growth — primary argument for short cycles and dose caps. forum
- Insulin resistance / feedback talk: Long unbroken runs framed as potentially blunting natural GH/IGF dynamics and glucose handling — lore-level, not routine assays in gym users. forum
- Receptor desensitization: Continuous multi-week-plus use framed as less efficient over time — drives on/off structure. forum
- Insulin / AAS stack risk: Multiplies glucose, fluid, and unknown interaction risk; insulin + DES is repeatedly labeled extreme. forum
- Source quality: Gray-market mislabel, underdosing, contamination, wrong peptide — structural vial risk independent of mechanism. forum
- Sterility / IM technique: Infection, nerve, or vessel injury risk with non-sterile or poorly placed IM shots. forum
- Who community lists as avoid: Active/prior cancer, proliferative retinopathy, poorly controlled diabetes, significant CVD, open growth plates / under ~25 in some guides, pregnancy — pathway-based caution lists, not DES-specific RCTs. forum
- Not proven safe: Research-chem status; missing a side effect in forum logs ≠ safety evidence. forum
- Mitogenic / cancer-pathway caution: IGF1R signaling is growth- and anti-apoptosis–related; active or recent malignancy is a hard community contraindication; theoretical tumor-support concern is standard IGF-class talk. trial
- Tested sport: WADA-prohibited growth-factor class; short half-life marketing does not make it “safe for tested competition.” trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.